Table 1. Fold-change in MIC/population/week (median of 3 tests/combination), relative to ancestral population.
| Week | |||||
| Treatment | Population | 1 | 2 | 3 | 4 |
| Iseganan | 1 | 8 | >8 | 4 | >16 |
| 2 | 8 | >8 | 4 | >16 | |
| 3 | 8 | 8 | ** | >16 | |
| 4 | 8 | 8 | 4 | >16 | |
| 5 | 8 | 8 | 4 | >16 | |
| Melittin | 1 | 4 | 4 | 8 | 32 |
| 2 | 2 | 2 | 8 | 4 | |
| 3 | 2 | 4 | 8 | 4 | |
| 4 | 2 | 2 | 16 | 16 | |
| 5 | 2 | 16 | 16 | 16 | |
| Pexiganan | 1 | 8 | 8 | l | l |
| 2 | 8 | 8 | l | l | |
| 3 | 8 | 4 | l | l | |
| 4 | 4 | 8 | l | l | |
| 5 | 8 | 4 | l | l | |
| Pexiganan & melittin 50∶50 | 1 | 2 | 1 | e | e |
| 2 | 2 | ** | e | e | |
| 3 | 4 | 4 | e | e | |
| 4 | 2 | 4 | e | e | |
| 5 | 4 | 2 | e | e | |
| Vancomycin | 1 | >64 | 32 | e | e |
| 2 | >64 | >64 | e | e | |
| 3 | >64 | 8 | e | e | |
| 4 | >64 | 32 | e | e | |
| 5 | >64 | 32 | e | e | |
| Streptomycin | 1 | >8 | >8 | >16 | >16 |
| 2 | >8 | >8 | >16 | >16 | |
| 3 | >8 | >8 | >16 | >16 | |
| 4 | >8 | >8 | >16 | >16 | |
| 5 | >8 | >8 | >16 | >16 | |
Zero observed inhibition is denoted by indication of MIC greater than the fold-change in MIC that would be inferred by MIC at the greatest concentration of stressor assayed.
**
data excluded due to low OD upon inoculation into MIC assays.
l: low-density (pexiganan) and e: extinct cultures.